ADHD drug enters phase II tests

Saegis' lead compound enters phase II in ADHD

Memory and cognition-focused biopharmaceutical firm Saegis Pharmaceuticals has initiated a phase II clinical study of its lead product candidate, SGS742, in adult ADHD patients

The phase II trial is a placebo-controlled, double-blind crossover study, where patients will be randomized to receive either placebo or active drug, and then crossed over to the alternate agent. The trial will measure improvement in standard ADHD scales, and is expected to be completed in Q3 2005.

"In preclinical and clinical studies, SGS742 has consistently shown positive benefits on the ability to improve attention, learning and memory," said Dr Rodney Pearlman, president and CEO of Saegis. "We are excited to be conducting an efficacy study among the adult ADHD population where safe, non-stimulatory medicines are needed."

Source: Saegis Marketing Release/Press Release